iRadimed (NASDAQ:IRMD) CEO Sells $437,550.00 in Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 5,000 shares of the business’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $87.51, for a total transaction of $437,550.00. Following the transaction, the chief executive officer owned 2,175,000 shares in the company, valued at approximately $190,334,250. This trade represents a 0.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

iRadimed Stock Up 3.5%

iRadimed stock traded up $3.04 during midday trading on Wednesday, hitting $90.40. 169,288 shares of the stock were exchanged, compared to its average volume of 90,268. iRadimed Corporation has a 52-week low of $50.88 and a 52-week high of $107.90. The stock has a market capitalization of $1.16 billion, a price-to-earnings ratio of 49.40 and a beta of 0.90. The business’s 50-day moving average price is $93.22 and its 200-day moving average price is $94.91.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings results on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.03. The business had revenue of $21.98 million for the quarter, compared to analysts’ expectations of $21.32 million. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. On average, sell-side analysts predict that iRadimed Corporation will post 1.52 earnings per share for the current fiscal year.

iRadimed Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 29th. Shareholders of record on Friday, May 15th will be paid a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Friday, May 15th. iRadimed’s payout ratio is presently 43.72%.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. Freedom Capital upgraded shares of iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. Weiss Ratings upgraded shares of iRadimed from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, May 6th. Lake Street Capital restated a “buy” rating and set a $120.00 price target on shares of iRadimed in a research note on Wednesday, February 11th. Finally, Roth Mkm restated a “buy” rating and set a $120.00 price target on shares of iRadimed in a research note on Tuesday, February 10th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, iRadimed has an average rating of “Buy” and an average price target of $120.00.

Institutional Trading of iRadimed

A number of institutional investors have recently modified their holdings of the business. Royal Bank of Canada increased its holdings in iRadimed by 14.7% during the 1st quarter. Royal Bank of Canada now owns 25,782 shares of the medical equipment provider’s stock worth $1,354,000 after acquiring an additional 3,307 shares during the period. AQR Capital Management LLC increased its holdings in iRadimed by 7.5% during the 1st quarter. AQR Capital Management LLC now owns 15,829 shares of the medical equipment provider’s stock worth $831,000 after acquiring an additional 1,108 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in iRadimed by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock worth $252,000 after acquiring an additional 234 shares during the period. Jones Financial Companies Lllp increased its holdings in iRadimed by 8,568.5% during the 1st quarter. Jones Financial Companies Lllp now owns 11,269 shares of the medical equipment provider’s stock worth $591,000 after acquiring an additional 11,139 shares during the period. Finally, Goldman Sachs Group Inc. increased its holdings in iRadimed by 1.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 169,387 shares of the medical equipment provider’s stock worth $8,889,000 after acquiring an additional 1,821 shares during the period. 92.34% of the stock is currently owned by hedge funds and other institutional investors.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.